Topaz Pharmaceuticals Receives $20 million Series A Financing

Published: Dec 03, 2007

PHILADELPHIA--(BUSINESS WIRE)--Topaz Pharmaceuticals Inc., a pharmaceutical company dedicated to the health and well being of children, today announced that it has secured $20 million in Series A financing from Aisling Capital (New York) and Fidelity Biosciences (Boston). The funds will be used to help Topaz complete clinical trials of the company’s new prescription medicine to fight head lice, and prepare the product for market.

Back to news